{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:56:06Z","timestamp":1790898966973,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T00:00:00Z","timestamp":1525651200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12032-018-1146-z","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T02:55:23Z","timestamp":1525661723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia"],"prefix":"10.1007","volume":"35","author":[{"given":"Maiko","family":"Abumiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kameoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-2425","authenticated-orcid":false,"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,7]]},"reference":[{"key":"1146_CR1","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567\u201376.","journal-title":"Blood"},{"key":"1146_CR2","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Br\u00fcmmendorf TH, Dyagil I, Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486\u201392.","journal-title":"J Clin Oncol"},{"key":"1146_CR3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1177\/0091270010387427","volume":"51","author":"R Abbas","year":"2011","unstructured":"Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol. 2011;51:1721\u20137.","journal-title":"J Clin Pharmacol"},{"key":"1146_CR4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","volume":"55","author":"R Abbas","year":"2016","unstructured":"Abbas R, Hsyu PH. Clinical pharmacokinetics and pharmacodynamics of bosutinib. Clin Pharmacokinet. 2016;55:1191\u2013204.","journal-title":"Clin Pharmacokinet"},{"key":"1146_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00228-016-2115-0","volume":"73","author":"PH Hsyu","year":"2017","unstructured":"Hsyu PH, Pignataro DS, Matschke K. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. Eur J Clin Pharmacol. 2017;73:57\u201363.","journal-title":"Eur J Clin Pharmacol"},{"key":"1146_CR6","unstructured":"Bosulif\u00ae (Bosutinib). Package Insert. Pfizer, Tokyo"},{"key":"1146_CR7","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1210\/me.2002-0421","volume":"17","author":"JM Rosenfeld","year":"2003","unstructured":"Rosenfeld JM, Vargas R Jr, Xie W, Evans RM. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol. 2003;17:1268\u201382.","journal-title":"Mol Endocrinol"},{"key":"1146_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2012.10.060","volume":"1491","author":"J Lemmen","year":"2013","unstructured":"Lemmen J, Tozakidis IE, Galla HJ. Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier. Brain Res. 2013;1491:1\u201313.","journal-title":"Brain Res"},{"issue":"3","key":"1146_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1124\/dmd.110.034983","volume":"39","author":"SS Gahir","year":"2011","unstructured":"Gahir SS, Piquette-Miller M. Gestational and pregnane X receptor-mediated regulation of placental ATP-binding cassette drug transporters in mice. Drug Metab Dispos. 2011;39(3):465\u201371.","journal-title":"Drug Metab Dispos"},{"key":"1146_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/00008571-200110000-00003","volume":"11","author":"J Zhang","year":"2001","unstructured":"Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR Jr, Schuetz EG, Boguski MS. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001;11:555\u201372.","journal-title":"Pharmacogenetics"},{"key":"1146_CR11","doi-asserted-by":"crossref","unstructured":"Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N. Correlation of plasma concentration and adverse effects of bosutinib in clinical practice at a single institution: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia. Exp Hematol Oncol. 2018, in press.","DOI":"10.1186\/s40164-018-0101-1"},{"key":"1146_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00228-008-0502-x","volume":"64","author":"Y Gao","year":"2008","unstructured":"Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol. 2008;64:877\u201382.","journal-title":"Eur J Clin Pharmacol"},{"key":"1146_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jso.20774","volume":"96","author":"L Wu","year":"2007","unstructured":"Wu L, Xu X, Shen J, Xie H, Yu S, Liang T, et al. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol. 2007;96:62\u20138.","journal-title":"J Surg Oncol"},{"key":"1146_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/BF02981939","volume":"73","author":"H Tanaka","year":"2001","unstructured":"Tanaka H, Imamura N, Oguma N, Shintani T, Tanaka K, Hyodo H, et al. Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. Int J Hematol. 2001;73:206\u201312.","journal-title":"Int J Hematol"},{"key":"1146_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1067\/mcp.2001.114164","volume":"69","author":"I Cascorbi","year":"2001","unstructured":"Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169\u201374.","journal-title":"Clin Pharmacol Ther"},{"key":"1146_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/dmd.104.001628","volume":"33","author":"D Kobayashi","year":"2005","unstructured":"Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos. 2005;33:94\u2013101.","journal-title":"Drug Metab Dispos"},{"key":"1146_CR17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1053\/j.gastro.2005.12.008","volume":"130","author":"MM Dring","year":"2006","unstructured":"Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology. 2006;130:341\u20138.","journal-title":"Gastroenterology"},{"key":"1146_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hep.20516","volume":"41","author":"Y Kimura","year":"2005","unstructured":"Kimura Y, Selmi C, Leung PS, Mao TK, Schauer J, Watnik M, et al. Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. Hepatology. 2005;41:55\u201363.","journal-title":"Hepatology"},{"key":"1146_CR19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.steroids.2008.04.002","volume":"73","author":"M Miura","year":"2008","unstructured":"Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Habuchi T, Suzuki T. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids. 2008;73:1052\u20139.","journal-title":"Steroids"},{"key":"1146_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1210\/er.2001-0038","volume":"23","author":"SA Kliewer","year":"2002","unstructured":"Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002;23:687\u2013702.","journal-title":"Endocr Rev"},{"key":"1146_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-015-0179-4","volume":"8","author":"S Redaelli","year":"2015","unstructured":"Redaelli S, Perini P, Ceccon M, Piazza R, Rigolio R, Mauri M, Boschelli F, Giannoudis A, Gambacorti-Passerini C. In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol. 2015;8:81.","journal-title":"J Hematol Oncol"},{"key":"1146_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12185-014-1722-8","volume":"101","author":"C Nakaseko","year":"2015","unstructured":"Nakaseko C, Takahashi N, Ishizawa K, Kobayashi Y, Ohashi K, Nakagawa Y, Yamamoto K, Miyamura K, Taniwaki M, Okada M, Kawaguchi T, Shibata A, Fujii Y, Ono C, Ohnishi K. A phase 1\/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. Int J Hematol. 2015;101:154\u201364.","journal-title":"Int J Hematol"},{"key":"1146_CR23","first-page":"2899","volume":"130","author":"M Garrett","year":"2017","unstructured":"Garrett M, Knight B, Cortes JE, Deininger MW. Optimizing dose of bosutinib to minimize adverse events while maintaining efficacy in patients with newly diagnosed chronic myelogenous leukemia. Blood. 2017;130: 2899 (ASH Annual Meeting Abstracts) .","journal-title":"Blood"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1146-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1146-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1146-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T13:06:57Z","timestamp":1557407217000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1146-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,7]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1146"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1146-z","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,7]]},"assertion":[{"value":"10 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors report that they have no relevant relationships to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"90"}}